- RecruitingPHASE1, PHASE2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
This study is looking at a new medicine called revumenib for different types of leukaemia that have come back or not responded to treatment. It aims to find the right dose and see how well it works and if it's safe for people with certain genetic changes in their leukaemia.
For: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Mixed Lineage Acute LeukemiaUnited States · Australia · Canada - Active not recruitingPHASE2
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
This study looks at a new drug, revumenib, with chemotherapy for babies and young children (under 6) with a type of leukaemia that has come back or isn't responding well to treatment, especially if they have a specific gene change.
For: Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageUnited States · Canada - RecruitingPHASE3
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
This study looks at a new drug, revumenib, combined with standard treatment for a type of blood cancer called AML. It's for patients whose AML has specific genetic changes (NPM1 or KMT2A) and who can't have strong chemotherapy.
For: Acute Myeloid Leukemia, AdultGermany · Netherlands · United Kingdom - RecruitingPHASE3
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
This study looks at adding a new medicine, revumenib, to standard chemotherapy for people with a specific type of newly diagnosed acute myeloid leukaemia (AML) with a particular gene change (NPM1 mutation). It aims to see if this combination works better and is safe.
For: Acute Myeloid LeukemiasAustralia · Austria · Belgium